文献速递复苏、休克与脓毒症创伤与烧伤重症综合管理与镇静镇痛

输血比例对严重创伤患者结局的动态影响:PROPPR随机临床试验的靶向机器学习分析

Dynamic impact of transfusion ratios on outcomes in severely injured patients: Targeted machine learning analysis of the Pragmatic, Randomized Optimal Platelet and Plasma Ratios randomized clinical trial.
PubMed 文献 · J Trauma Acute Care Surg · 2020-01-01
一句话结论PROPPR试验的机器学习分析提示,输血比例对止血的影响是动态的:入院后3小时内未止血者,接受较高血浆/血小板与红细胞比例可加速止血;总体输血比例对死亡率随时间无显著影响。

该研究基于PROPPR三期随机对照试验(北美12家一级创伤中心,2012至2013年,680例需大量输血的严重创伤患者),用半参数机器学习与因果推断方法补充意向性治疗分析,估计入院后24小时内不同时间点输血比例与死亡率和止血的动态关系。意向性治疗分析中1:1:1组死亡率有降低趋势但无统计学显著性;止血时间超过2小时的患者中,1:1:1比例与更高止血概率相关,自第4小时起有统计学显著性。符合方案的实际输血比例分析中,四个连续时间段内实际比例与死亡率均无显著关联;同时接受高血浆/红细胞和高血小板/红细胞比例者与两者均低者相比,入院后第3小时达到止血的相对危险度为2.49(95%CI 1.19-5.22)。作者认为输血比例对止血的影响是动态的,对入院3小时内未止血者提高血小板和血浆与红细胞的比例可加速止血。

要点

  • PROPPR意向性治疗分析中1:1:1组死亡率有降低趋势但无统计学显著性。
  • 止血时间超过2小时的患者,1:1:1比例与更高止血概率相关,自第4小时起有统计学显著性。
  • 符合方案分析中,四个连续时间段内实际输血比例与死亡率均无显著关联。
  • 同时高血浆/红细胞和高血小板/红细胞比例者 vs 两者均低者,入院后第3小时止血的相对危险度为2.49(95%CI 1.19-5.22)。
  • 作者认为输血比例对止血的影响是动态的,对入院3小时内未止血者提高血小板和血浆与红细胞比例可加速止血。

适用人群与场景

  • PROPPR纳入的需大量输血的严重创伤患者,来自北美12家一级创伤中心,2012至2013年,共680例。

研究设计与关键结果

  • 研究类型:基于PROPPR三期随机对照试验的靶向机器学习与因果推断分析,PROPPR为北美12家一级创伤中心、2012至2013年、680例需大量输血的严重创伤患者。
  • 意向性治疗分析:1:1:1组死亡率有降低趋势,但无统计学显著性。
  • 止血时间超过2小时的患者中,1:1:1比例与更高止血概率相关,自第4小时起有统计学显著性。
  • 符合方案的实际输血比例分析:四个连续时间段内,实际比例与死亡率均无显著关联。
  • 同时接受高血浆/红细胞和高血小板/红细胞比例者与两者均低者相比,入院后第3小时达到止血的相对危险度为2.49(95%CI 1.19-5.22)。

证据类型、等级与局限

  • 证据类型:基于随机对照试验(PROPPR)的二次分析,证据等级为治疗性IV级。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为输血比例对止血的影响是动态的;对入院3小时内尚未止血的严重创伤患者,接受较高血小板和血浆与红细胞比例可加速止血。
  • 总体输血比例对死亡率随时间无显著影响,意向性治疗分析中1:1:1组死亡率降低趋势未达统计学显著性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Massive transfusion protocols to treat postinjury hemorrhage are based on predefined blood product transfusion ratios followed by goal-directed transfusion based on patient's clinical evolution. However, it remains unclear how these transfusion ratios impact patient outcomes over time from injury.

METHODS: The Pragmatic, Randomized Optimal Platelet and Plasma Ratios (PROPPR) is a phase 3, randomized controlled trial, across 12 Level I trauma centers in North America. From 2012 to 2013, 680 severely injured patients required massive transfusion. We used semiparametric machine learning techniques and causal inference methods to augment the intent-to-treat analysis of PROPPR, estimating the dynamic relationship between transfusion ratios and outcomes: mortality and hemostasis at different timepoints during the first 24 hours after admission.

RESULTS: In the intention-to-treat analysis, the 1:1:1 group tended to have decreased mortality, but with no statistical significance. For patients in whom hemostasis took longer than 2 hours, the 1:1:1 ratio was associated with a higher probability of hemostasis, statistically significant from the 4 hour on. In the per-protocol, actual-transfusion-ratios-received analysis, during four successive time intervals, no significant association was found between the actual ratios and mortality. When comparing patient groups who received both high plasma/PRBC and high platelet/PRBC ratios to the group of low ratios in both, the relative risk of achieving hemostasis was 2.49 (95% confidence interval, 1.19-5.22) during the third hour after admission, suggesting a significant beneficial impact of higher transfusion ratios of plasma and platelets on hemostasis.

CONCLUSION: Our results suggest that the impact of transfusion ratios on hemostasis is dynamic. Overall, the transfusion ratios had no significant impact on mortality over time. However, receiving higher ratios of platelets and plasma relative to red blood cells hastens hemostasis in subjects who have yet to achieve hemostasis within 3 hours after hospital admission.

LEVEL OF EVIDENCE: Therapeutic IV.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Nguyen M, Pirracchio R, Kornblith LZ, et al. Dynamic impact of transfusion ratios on outcomes in severely injured patients: Targeted machine learning analysis of the Pragmatic, Randomized Optimal Platelet and Plasma Ratios randomized clinical trial. J Trauma Acute Care Surg. 2020. PMID: 32520897. doi:10.1097/TA.0000000000002819

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。